Global Phage Therapy Market

1
Global Phage Therapy Market

• (Bacteriophage Market Virus Campylobacter,
  Salmonella, Escherichia coli, Listeria,
  Klebsiella, and Staphylococcus spp., Key Players
  Armata Pharmaceuticals, Inc, Micreos,
  TechnoPhage) Industry Scenario, Market Size,
  Outlook, Trend and Forecast 2019 2028

sales_at_accurizemarketresearch.com Copyright 2021
Accurize Market Research
2
Global Phage Therapy Market

• Global phage therapy market is expected to
  foresee a compound annual growth rate of 8.1
  from 2021 to 2028. The major factors driving the
  growth of the phage therapy market
  are antibiotics resistance, the increased
  prevalence of food-borne diseases, use of phage
  therapy in the food beverage industry,
  application of bacteriophage specific to target
  bacteria, extensive research development, and
  increasing antimicrobial resistance. Nowadays
  antibiotics resistance has become one of the
  biggest threats to global health as it can affect
  people of any age group. Misuse and overuse of
  antibiotics by people is leading to antibiotic
  resistance. Hence, scientists across the globe
  are expecting that the traditional use of
  antibiotics would be replaced by modernized
  bacteriophages or phage therapies. Also, few
  people are allergic to antibiotics as a result
  phage therapy could be a useful alternative for
  such patients.

sales_at_accurizemarketresearch.com Copyright 2021
Accurize Market Research
3

• Phage therapy also known as Bacteriophage is
  specific to the bacteria they infect and do not
  harm other beneficial bacteria present in the
  body and affect the microbial ecosystem of the
  body. Bacteriophages can be administrated to
  patients in many different ways which include
  oral consumption, external application, and
  surgical treatment. Phages consist mostly of
  nucleic acids and proteins thus they are
  inherently non-toxins. Bacteriophages against
  many bacteria are easily discovered and
  additionally, they are versatile in terms of
  formulation development which includes the
  ability to get combined with any other
  antibiotics. Furthermore, the production of phage
  therapy is simple and relatively inexpensive.
  Clinical trials of bacteriophage to cure diseases
  such as HIV Infection, Wound Infections, Urinary T
  ract Infection Bacterial, Acute Tonsillitis,
  Venous Leg Ulcers, Covid19, Tuberculosis, Cystic
  Fibrosis, Mild Gastrointestinal, Primary Immune
  Deficiency Diseases, Bacterial Infections,
  Prostate Cancer and many others are being
  conducted in future, bacteriophage therapy could
  replace antibiotic treatments of these diseases.
  Bacteriophages therapies are still under clinical
  trials and company pipelines, hence it cannot be
  claimed to be entirely reliable. In addition,
  bacteriophages are viruses that tend to swap
  genes with each other and other organisms with
  which they come into contact. Hence, there is a
  chance of the spread of antibiotic resistance in
  bacteria. These are some of the factors that
  would slightly slow down the acceptance in the
  phage therapy market.

sales_at_accurizemarketresearch.com Copyright 2021
Accurize Market Research
4

• Bacteriophage plays a significant role in the
  food industry due to the increased prevalence of
  food-borne diseases that are caused due to food
  spoilage and this is boosting the growth of the
  bacteriophage market, as spoiled food contains
  pathogenic bacteria and viruses. The interest in
  characteristic antimicrobial builds has expanded
  because of changes in shopper positions towards
  the utilization of substance additives in staple
  and food handling surfaces. Bacteriophages fit in
  the class of characteristic antimicrobial and
  their adequacy in controlling bacterial microbes
  in the agro-food industry has prompted the
  advancement of various phage items previously
  endorsed by USFDA and USDA.
• Bacteriophages are highly specific to target
  bacteria
• and bacteriophages do not affect human cells
• directly. The primary bit of scope is the
  explicitness
• of bacteriophages and medicines that can be
• intended to explicitly target pathogenic
• microorganisms while not adversely influencing
  the
• ordinary microbiota. Another possible issue with
  phage
• treatment incorporates the improvement of
  resistance and
• constraints with the enrolment of phage treatment
  
• alternatives. Increased antimicrobial resistance
  in
• bacteriophage therapy is driving the global
  bacteriophage
• therapy market growth. For instance, in 2017, the
  World
• Health Organization (WHO) published a list of
  global priority
• pathogens comprising 12 species of bacteria
  categorized into critical, high, and medium
  priority based on their level of resistance. It
  is believed that bacteriophage therapy would be
  replacing the traditional use of antibiotics as
  extensive use of antibiotics is increasing the
  risk of antimicrobial resistance.

sales_at_accurizemarketresearch.com Copyright 2021
Accurize Market Research
5

• The major limiting component for the
  development/extension of the worldwide phage
  therapy market is the absence of prepared
  technicians, experts, and specialists in the
  field. In addition, the high risk of product
  failure for drug development is another factor
  restraining the market growth. Several companies
  operating in the bacteriophage therapy market are
  investing and focusing on developing advanced
  bacteriophage platforms. In addition, the
  emerging economy is providing booming
  opportunities in the global bacteriophage market,
  as there has been an increase in the patient
  population in the health care sector. For
  instance, Armata Pharmaceuticals, Inc. Adaptive
  Phage Therapeutics, Phagelux, SNIPR BIOME,
  Microgen Russia, BiomX (MBcure Ltd.), Enbiotix,
  Eligo Bioscience, MicroPhage Inc., Phage
  International, Intralytix, Inc, InnoPhage,
  iNtODEWorld, Locus Biosciences among others are
  the leading players in the global bacteriophage
  market.
• North America holds a substantial share in the
  global phage therapy market, inferable from the
  increment in bacteriophage clinical path. For
  example, as per UC San Diego Health 2019
  investigation, the U.S. Food and Drug
  Administration (USFDA) has given leeway for the
  clinical path in the U.S. to test IV directed
  bacteriophage-based treatment to execute drug
  opposition.
• The global phage therapy market is segmented
  into by bacteria, by product, by application,
  and geography Geographically, North America is
  anticipated to have the largest market share over
  the next seven years and the growth is attributed
  to the early adoption of new and emerging
  technologies coupled with expanding volumes of
  data. However, Asia Pacific is expected to
  witness the highest compound annual growth rate
  (CAGR) in the Phage Therapy market. The major
  geographies covered under the scope of Global
  Phage Therapy are North America, Asia Pacific,
  Europe, and the Rest of the Global (RoW). North
  America is further segmented into the U.S.,
  Mexico, and Canada. Europe is segmented into the
  UK, Germany, France, Italy, Spain, and the Rest
  of Europe. The key countries covered under the
  Asia Pacific are Japan, China, India, South
  Korea, Australia, and the Rest of the Asia
  Pacific. Similarly, the Rest of the World (RoW)
  is bifurcated into South Central America,
  Middle East, and Africa.

sales_at_accurizemarketresearch.com Copyright 2021
Accurize Market Research
6

• Armata Pharmaceuticals, Inc. Adaptive Phage
  Therapeutics, Phagelux, SNIPR BIOME, Microgen
  Russia, BiomX (MBcure Ltd.), Enbiotix, Eligo
  Bioscience, MicroPhage Inc., Phage International,
  Intralytix, Inc, InnoPhage, iNtODEWorld, Locus
  Biosciences, PhagoMed Biopharma GmbH, Pherecydes
  Pharma SA, TechnoPhage, Eliava Biopreparations
  Ltd., Nextbiotics, PhagePro, Inc, Phi
  Therapeutics, Fixed-phage Ltd, Micreos BV and
  ContraFect Corporation are the prominent players
  of the global bacteriophages market.
• Years Covered in the Report 2019 - 2028
• Base Year 2020
• Forecast Years 2021 - 2028

sales_at_accurizemarketresearch.com Copyright 2021
Accurize Market Research
7
Scope of Global Phage Therapy Market/
Bacteriophage Market

• HUMAN PHAGE THERAPY DISEASES AND BACTERIA BY
  REGION, 2021 2027
• LIST OF PHAGE THERAPY PIPELINE
• The market is segmented on the basis of by
  Bacteria, Product, by Application, and by Region.
• Market Segmentation by Bacteria (Revenue, USD
  Million, 2019 - 2028)
• Salmonella
• Streptococcus
• Escherichia Coli
• Others
• Market Segmentation by Product (Revenue, USD
  Million, 2019 - 2028)
• Oral Consumption
• External applications
• Surgical treatment

sales_at_accurizemarketresearch.com Copyright 2021
Accurize Market Research
8
Market Segmentation by Region/ Geography/ Country
(Revenue, USD Million, 2019 - 2028)

• Market Segmentation by Product (Revenue, USD
  Million, 2019 - 2028)
• Oral Consumption
• External applications
• Surgical treatment
• Market Segmentation by Application (Revenue, USD
  Million, 2019 - 2028)
• Human medicines
• Veterinary science
• Food
• Others (Agriculture, dentistry, etc.)

sales_at_accurizemarketresearch.com Copyright 2021
Accurize Market Research
9
Asia PacificChinaJapanIndiaSouth
KoreaTaiwanSingaporeAustraliaRest of Asia
PacificRest of the World (RoW)Central South
AmericaMiddle EastAfrica
Market Segmentation by Region/ Geography/ Country
(Revenue, USD Million, 2019 - 2028)

• North America
• The U.S.
• Mexico
• Canada
• Europe
• The U.K.
• Germany
• France
• Italy
• Spain
• Belgium
• Switzerland
• Netherlands
• Rest of Europe

sales_at_accurizemarketresearch.com Copyright 2021
Accurize Market Research
10
Contact Us

• Accurize Market Research Pvt. Ltd.
• PATNA OFFICE K-129,
• PC COLONY,
• HANUMAN NAGAR,
• KANKARBAGH, PATNA, PIN-800020
• Emailhelp_at_accurizemarketresearch.com
• CONTACT NO1-339-368-6383

sales_at_accurizemarketresearch.com Copyright 2021
Accurize Market Research